SCHEMBL17830693

SCHEMBL17830693

COc1ccc(COC(=O)CN2C(=O)/C(=C3\SC(=S)N(CCC(=O)O)C3=O)c3cc(Cl)ccc32)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN7 P35236 2/20 0.60
CACNA1B Q00975 2/20 0.60
APBA1 Q02410 2/20 0.60
PTPN22 Q9Y2R2 2/20 0.60
APOBEC3G Q9HC16 1/20 0.60
KAT2B Q92831 5/20 0.56
CREBBP Q92793 4/20 0.56
KAT2A Q92830 4/20 0.56
EP300 Q09472 3/20 0.56
APEX1 P27695 3/20 0.52
MEN1 O00255 3/20 0.49
KMT2A Q03164 3/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
DUSP3 P51452 1/20 0.47
PTPN12 Q05209 1/20 0.47
MAPT P10636 3/20 0.45
ALDH1A1 P00352 2/20 0.45
NCOA3 Q9Y6Q9 1/20 0.45
PTGES O14684 1/20 0.43
TAS2R14 Q9NYV8 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17832352 0.94 APEX1 (0.57) PTPN7CACNA1BAPBA1PTPN22APOBEC3G
SCHEMBL17830695 0.92 KAT2B (0.54) PTPN7CACNA1BAPBA1PTPN22APOBEC3G
SCHEMBL17830694 0.92 PTPN7 (0.56) PTPN7CACNA1BAPBA1PTPN22APOBEC3G
SCHEMBL17830705 0.91 APEX1 (0.61) PTPN7CACNA1BAPBA1PTPN22APOBEC3G
SCHEMBL17830699 0.91 MEN1 (0.61) PTPN7CACNA1BAPBA1PTPN22APOBEC3G
SCHEMBL17830697 0.88 APEX1 (0.51) PTPN7CACNA1BAPBA1PTPN22APOBEC3G
SCHEMBL16366716 0.88 KAT2B (0.57) PTPN7CACNA1BAPBA1PTPN22APOBEC3G
SCHEMBL17830698 0.88 APEX1 (0.57) PTPN7CACNA1BAPBA1PTPN22APOBEC3G
SCHEMBL17830696 0.87 APEX1 (0.54) PTPN7CACNA1BAPBA1PTPN22APOBEC3G
SCHEMBL17830704 0.87 APEX1 (0.61) PTPN7CACNA1BAPBA1PTPN22APOBEC3G

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-9943506-B2 BCL6 inhibitors as anticancer agents CORNELL UNIVERSITY (US) 2018-04-17 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS CORNELL UNIVERSITY 2016-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160166549-A1 BCL6 INHIBITORS AS ANTICANCER AGENTS BCL6, BCL6B, BAZ2A PTPN7 720/4885CACNA1B 3809/4885APBA1 1660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.